Pfizer Reports Positive Trial Results for Colorectal Cancer Treatment
Pfizer announced positive results from a BREAKWATER trial cohort for BRAFTOVI in metastatic colorectal cancer, showing a 64% response rate. The company also received recent analyst ratings.